Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampion in osteoarthritis of the knee
NCT02024529Phase 3Completed
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Jan 2014
- Primary completion
- May 2014
- Modality
- Small Molecules, Cyclic Peptides
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing Ampion with Placebo (2 arms). Primary endpoint: Change in WOMAC A Pain at 12 weeks. Started Jan 2014; status: completed.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02024529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024529.